Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01915589




Registration number
NCT01915589
Ethics application status
Date submitted
24/07/2013
Date registered
5/08/2013
Date last updated
8/04/2021

Titles & IDs
Public title
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
Scientific title
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Secondary ID [1] 0 0
2013-000311-25
Secondary ID [2] 0 0
16553
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Hepatocellular 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Refametinib (BAY86-9766)

Experimental: Refametinib (BAY86-9766) - For purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Death Unacceptable toxicity Subject withdraws consent Substantial non-compliance with the protocol Treating physician determines discontinuation of treatment is in the subject's best interest. Radiological progression as determined by RECIST (Version 1.1) or mRECIST criteria or clinical progression (e.g. Eastern Cooperative Oncology group performance status - ECOG PS =3) patients may continue to receive study treatment if identified as having continued clinical benefit as judged by the treating physician.


Treatment: Drugs: Refametinib (BAY86-9766)
All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review
Timepoint [1] 0 0
Approximately 36 months
Secondary outcome [1] 0 0
Objective tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central radiological review
Timepoint [1] 0 0
Approximately 36 months
Secondary outcome [2] 0 0
Objective tumor response according to RECIST 1.1 and mRECIST assessed by investigators
Timepoint [2] 0 0
Approximately 36 months
Secondary outcome [3] 0 0
Disease control (central and investigator's assessment)
Timepoint [3] 0 0
Approximately 36 months
Secondary outcome [4] 0 0
Overall survival
Timepoint [4] 0 0
Approximately 36 months
Secondary outcome [5] 0 0
Time to radiographic tumor progression (central and investigator's assessment)
Timepoint [5] 0 0
Approximately 36 months
Secondary outcome [6] 0 0
Duration of response (central and investigator's assessment)
Timepoint [6] 0 0
Approximately 36 months
Secondary outcome [7] 0 0
Time to objective response (central and investigator's assessment)
Timepoint [7] 0 0
Approximately 36 months
Secondary outcome [8] 0 0
Change in tumor size (central and investigator's assessment)
Timepoint [8] 0 0
Approximately 36 months
Secondary outcome [9] 0 0
Best overall response (central and investigator's assessment)
Timepoint [9] 0 0
Approximately 36 months
Secondary outcome [10] 0 0
Progression-free survival (central and investigator's assessment)
Timepoint [10] 0 0
Approximately 36 months
Secondary outcome [11] 0 0
Number of participants with adverse events as a measure of safety and tolerability
Timepoint [11] 0 0
Approximately 36 months

Eligibility
Key inclusion criteria
Eligibility criteria for RAS mutation testing

* Unresectable or metastatic HCC, confirmed either by histology or clinically according to the American Association for the Study of Liver Disease (AASLD) criteria for cirrhotic patients. For non-cirrhotic patients, histological confirmation is mandatory.
* Male or female =18 years of age.
* Eastern Cooperative Oncology Group (ECOG) performance state 0 or 1.
* Life expectancy of at least 12 weeks.
* No prior use of targeted agents, experimental therapy or systemic anti-cancer treatment for HCC (except sorafenib)
* No previous treatment with refametinib(BAY86-9766). Criteria for study treatment eligibility
* Patient must harbor GTPase Kirsten rat sarcoma viral oncogene homolog (KRAS) or Neuroblastoma RAS viral oncogene homolog (NRAS) mutation based on Beads, emulsions, amplification, and magnetic technology, sensitive mutation detection (BEAMing) plasma test.
* Patients must have at least one uni-dimensional measurable lesion by Computed tomography (CT) or Magnetic resonance (MR) according to RECIST 1.1 and mRECIST which is either naïve (not previously treated by local therapy such as surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) or previously treated and has progressed until baseline (both measureable lesion and/or progressed lesion have to be confirmed by central image review of baseline and progression scan).
* ECOG performance status of 0 or 1.
* Liver function status of Child-Pugh Class A.
* Adequate bone morrow, liver, and renal function
* Patient has within normal range cardiac function confirmed by the enrolling clinical institute as measured by echocardiogram or multiple gated acquisition (MUGA) scan.
* Patients who are therapeutically anti-coagulated with an agent such as warfarin or heparin are allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluations will be performed until International normalized ratio (INR) is stable (within Child Pugh class A threshold) based on a measurement at pre-dose, as defined by the local standard of care.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any Cancer curatively treated < 3 years prior to study entry, except cervical carcinoma in situ (CIS), treated basal cell carcinoma, and superficial bladder tumors [Staging: noninvasive papillary tumor (Ta), CIS carcinoma (Tis) and tumor invades lamina propria (T1)]
* Subjects who are eligible for surgery, liver transplantation, ablation or transarterial chemoembolization for HCC.
* History of cardiac disease
* Uncontrolled hypertension (systolic blood pressure [BP] >150 mmHg or diastolic blood pressure > 90 mmHg despite optimal medical management).
* Ongoing infection > Grade 2 according to National Cancer Institute - Common Toxicity Criteria for Adverse Events version 4.03 (NCI-CTCAE version 4.03) Hepatitis B is allowed if no active replication (defined as abnormal Alanine aminotransferase [ALT] >2x Upper limit normal [ULN] associated with Hepatitis B virus [HBV] DNA >20,000 IU/mL) is present. Hepatitis C is allowed if no antiviral treatment is required.
* Known history of, or symptomatic metastatic brain or meningeal tumors (head CT or MR at Screening to confirm the absence of central nervous system [CNS] disease if patient had symptoms suggestive or consistent with CNS disease).
* History of interstitial lung disease (ILD).
* History of hepatic encephalopathy.
* History of organ allograft, cornea transplantation will be allowed.
* History or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
* Visible retinal pathology as assessed by ophthalmologic exam that was considered a risk factor for RVO or CSR.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/09/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
8/10/2014
Sample size
Target
Accrual to date
Final
16
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
District of Columbia
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
New York
Country [4] 0 0
Austria
State/province [4] 0 0
Graz
Country [5] 0 0
Belgium
State/province [5] 0 0
Bruxelles - Brussel
Country [6] 0 0
Belgium
State/province [6] 0 0
Charleroi
Country [7] 0 0
Belgium
State/province [7] 0 0
Gent
Country [8] 0 0
Belgium
State/province [8] 0 0
Leuven
Country [9] 0 0
Czechia
State/province [9] 0 0
Praha 2
Country [10] 0 0
France
State/province [10] 0 0
CLERMONT-FERRAND Cedex 1
Country [11] 0 0
France
State/province [11] 0 0
Creteil
Country [12] 0 0
France
State/province [12] 0 0
Lille
Country [13] 0 0
France
State/province [13] 0 0
Marseille
Country [14] 0 0
France
State/province [14] 0 0
Montpellier Cedex
Country [15] 0 0
France
State/province [15] 0 0
Vandoeuvre-les-nancy
Country [16] 0 0
Germany
State/province [16] 0 0
Baden-Württemberg
Country [17] 0 0
Germany
State/province [17] 0 0
Bayern
Country [18] 0 0
Germany
State/province [18] 0 0
Niedersachsen
Country [19] 0 0
Germany
State/province [19] 0 0
Nordrhein-Westfalen
Country [20] 0 0
Germany
State/province [20] 0 0
Rheinland-Pfalz
Country [21] 0 0
Germany
State/province [21] 0 0
Berlin
Country [22] 0 0
Hong Kong
State/province [22] 0 0
Shatin
Country [23] 0 0
Hungary
State/province [23] 0 0
Budapest
Country [24] 0 0
Hungary
State/province [24] 0 0
Debrecen
Country [25] 0 0
Italy
State/province [25] 0 0
Lombardia
Country [26] 0 0
Japan
State/province [26] 0 0
Chiba
Country [27] 0 0
Japan
State/province [27] 0 0
Hyogo
Country [28] 0 0
Japan
State/province [28] 0 0
Osaka
Country [29] 0 0
Japan
State/province [29] 0 0
Shizuoka
Country [30] 0 0
Japan
State/province [30] 0 0
Tochigi
Country [31] 0 0
Japan
State/province [31] 0 0
Tokyo
Country [32] 0 0
Korea, Republic of
State/province [32] 0 0
Busan
Country [33] 0 0
Korea, Republic of
State/province [33] 0 0
Daegu
Country [34] 0 0
Korea, Republic of
State/province [34] 0 0
Seoul
Country [35] 0 0
New Zealand
State/province [35] 0 0
Auckland
Country [36] 0 0
Spain
State/province [36] 0 0
A Coruña
Country [37] 0 0
Spain
State/province [37] 0 0
Catalunya
Country [38] 0 0
Spain
State/province [38] 0 0
Alicante
Country [39] 0 0
Spain
State/province [39] 0 0
Pontevedra
Country [40] 0 0
Spain
State/province [40] 0 0
Valencia
Country [41] 0 0
Switzerland
State/province [41] 0 0
Genève
Country [42] 0 0
Switzerland
State/province [42] 0 0
Bern
Country [43] 0 0
Taiwan
State/province [43] 0 0
Kaohsiung City
Country [44] 0 0
Taiwan
State/province [44] 0 0
Tainan
Country [45] 0 0
Thailand
State/province [45] 0 0
Bangkok
Country [46] 0 0
United Kingdom
State/province [46] 0 0
West Midlands

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a study to investigate the potential clinical benefit of refametinib in patients with unresectable or metastatic HCC carrying a RAS mutation. The study will be conducted in 2 stages. Approximately 95 patients (15 at Stage 1/ 80 at Stage 2) will be accrued to this study to receive treatment. Stage 2 of the trial will only be conducted if at least 5 out of 15 patients at Stage 1 show at least confirmed partial response (PR) according to modified response evaluation criteria in solid tumors (mRECIST) assessed by central image review.

Refametinib is an oral (i.e. taken by mouth) protein kinase inhibitor. A kinase inhibitor targets certain key proteins that are essential for the survival of the cancer cell. By specifically targeting these proteins, refametinib may stop cancer growth. The growth of the tumor may be decreased by preventing these specific proteins from functioning.

The primary endpoint (the most meaningful result to be tracked) of this study is based on the rate of response, i.e. the disease getting smaller. The aim is to show that the therapy with refametinib improves the response rate in this RAS mutation patient population.
Trial website
https://clinicaltrials.gov/study/NCT01915589
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01915589